buyWeak
Matthew Gall bought $42k of ITOS
Chief Financial Officer at iTeos Therapeutics, Inc.. 5,000 shares at an average of $8.37, traded Oct 12, 2023, filed Oct 12, 2023.
Conviction score
34Value
$42k
5,000 shares
Holdings after
19,429
+35% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +6Trade size$42k at market
- +6Relative to holdingsHoldings up 35%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-052709, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 12, 2023 | POpen-market purchase Common Stock | +5,000 | $8.37 | $42k | 19,429 | Oct 12, 2023 |
Related signals
Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.0M 104,565 shares | -72% | |
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.6M 156,847 shares | -109% | |
| 33Weak | iTeos Therapeutics, Inc. | David Hallal director | $1.2M 114,682 shares | -300% | |
| 42Moderate | ITOSbuy iTeos Therapeutics, Inc. | EcoR1 Capital, LLC owner | $39M 4,958,978 shares | +87% | |
| 53Moderate | iTeos Therapeutics, Inc. | MPM BioVentures 2014, L.P. other | $5.1M 630,191 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Ansbert Gadicke other | $8.3M 1,031,931 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Mpm Bioventures 2018, L.p. other | $5.1M 630,191 shares | -23% | |
| 31Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $39k 5,000 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.